Literature DB >> 17414109

Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis.

M Isabel Fiel1, Swan N Thung, Prodromos Hytiroglou, Sukru Emre, Thomas D Schiano.   

Abstract

Hepatoportal sclerosis (HPS) is one of the causes of noncirrhotic portal hypertension. In general, hepatic synthetic function is preserved and treatment is aimed at relief of the portal hypertension. In this study, we present the clinical and pathologic features of HPS cases who underwent liver transplantation (LT). LT cases with confirmed gross and microscopic diagnosis of HPS are included. Weight of the explanted liver, presence of thrombi in the main blood vessels, and gross and microscopic characteristics were assessed. Clinical information was gathered from chart review. From 1995 to 2004, 8 LT patients were diagnosed with HPS. Cirrhosis resulting from alcohol (2), autoimmune hepatitis (2), and hepatitis B (1), or cryptogenic cirrhosis (3) was the presumed diagnoses pre-LT. Seven patients presented with bleeding varices and 5 had concomitant ascites. At the time of LT, mean values were: prothrombin time of 15.2 seconds, serum albumin 3.2 g/dL, serum bilirubin 3.5 mg/dL, alkaline phosphatase 140 IU/L, aspartate aminotransferase 39.4 IU/L, and alanine aminotransferase 34.7 IU/L. Explanted livers were shrunken, with weights ranging from 715 to 1199 g (mean 934). Nonocclusive portal vein thrombosis was present in 2 patients. On histologic examination, there was dense portal fibrosis, marked phlebosclerosis, and presence of variable degrees of megasinusoid formation. Four livers also had features of incomplete septal cirrhosis. None showed histologic features of the presumed underlying liver disease. In conclusion, HPS can cause hepatic synthetic dysfunction that may necessitate LT. Small liver volume, significant portal fibrosis, and phlebosclerosis may contribute to hepatic parenchymal loss and subsequent synthetic compromise.

Entities:  

Mesh:

Year:  2007        PMID: 17414109     DOI: 10.1097/01.pas.0000213425.76621.f1

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV.

Authors:  Thomas D Schiano; Alison Uriel; Douglas T Dieterich; M Isabel Fiel
Journal:  Virchows Arch       Date:  2010-11-06       Impact factor: 4.064

2.  Non-cirrhotic portal fibrosis related end stage liver disease in adults: evaluation from a study on living donor liver transplant recipients.

Authors:  Sanjiv Saigal; Nabeen C Nayak; Deepali Jain; Vinay Kumaran; Ravi Mohanka; Neeraj Saraf; Amit Rastogi; Naimesh Mehta; Samiran Nundy; Arvinder Soin
Journal:  Hepatol Int       Date:  2011-01-12       Impact factor: 6.047

Review 3.  Pathology of idiopathic non-cirrhotic portal hypertension.

Authors:  Maria Guido; Samantha Sarcognato; Diana Sacchi; Guido Colloredo
Journal:  Virchows Arch       Date:  2018-04-12       Impact factor: 4.064

4.  Elevated levels of circulating angiotensin converting enzyme in patients with hepatoportal sclerosis.

Authors:  Yavuz Beyazit; Mehmet Ibis; Tugrul Purnak; Turan Turhan; Murat Kekilli; Mevlut Kurt; Abdurrahim Sayilir; Ibrahim Koral Onal; Nesrin Turhan; Adnan Tas; Seyfettin Köklü; Ibrahim C Haznedaroglu
Journal:  Dig Dis Sci       Date:  2011-02-03       Impact factor: 3.199

5.  Surgical portosystemic shunts and the Rex bypass in children: a single-centre experience.

Authors:  Sukru Emre; Christina Dugan; Tamara Frankenberg; Lisa Cooper Hudgins; Rosemarie Gagliardi; A Tarik Artis; Gonzalo Rodriguez-Laiz; Gabriel Gondolesi; Benjamin L Shneider; Nanda Kerkar
Journal:  HPB (Oxford)       Date:  2009-05       Impact factor: 3.647

Review 6.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

7.  Portal vein thrombosis leading to pre-sinusoidal non-cirrhotic portal hypertension resulting in decreased synthetic function of the liver.

Authors:  Kevin Kline; Muhannad Al Hanayneh; Mohammad Bilal; Heather Stevenson-Lerner
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

8.  Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study.

Authors:  Shantha Ram Valainathan; Riccardo Sartoris; Laure Elkrief; Marta Magaz; Fabian Betancourt; Silvia Pellegrino; Arianna Nivolli; Marco Dioguardi Burgio; Yves Flattet; Sylvain Terraz; Nicolas Drilhon; Marie Lazareth; Julia Herrou; Onorina Bruno; Audrey Payance; Aurélie Plessier; François Durand; Maxime Ronot; Dominique-Charles Valla; Valérie Paradis; Juan Carlos Garcia-Pagan; Valérie Vilgrain; Pierre-Emmanuel Rautou
Journal:  Hepatology       Date:  2022-02-16       Impact factor: 17.298

9.  Hepatoportal sclerosis in childhood: descriptive analysis of 12 patients.

Authors:  Mustafa Serdar Cantez; Nelgin Gerenli; Vildan Ertekin; Mine Güllüoğlu; Özlem Durmaz
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

Review 10.  Idiopathic Noncirrhotic Portal Hypertension: An Appraisal.

Authors:  Hwajeong Lee; Aseeb Ur Rehman; M Isabel Fiel
Journal:  J Pathol Transl Med       Date:  2015-11-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.